Cagrilintide Research: Amylin Analogue Data

Summary

Cagrilintide is a long-acting amylin analogue investigated alone and in fixed combination with semaglutide (CagriSema). Amylin is a pancreatic hormone co-secreted with insulin that signals satiety through a different route from GLP-1, which is why combining the two is of interest. It is not approved.

Last reviewed 2026-09-01

What it is

Cagrilintide is a synthetic, acylated analogue of human amylin (islet amyloid polypeptide) engineered for non-aggregation and once-weekly dosing. It is a non-selective agonist at amylin and calcitonin receptors.

Native human amylin aggregates readily, which blocked its development. Pramlintide, a non-aggregating analogue, was approved in 2005 but required mealtime dosing. Cagrilintide was designed to solve the half-life problem.

Synthetic analogue of an endogenous pancreatic beta-cell hormone.

Amylin signals satiety through hindbrain circuits partly distinct from GLP-1, offering a genuinely additive rather than overlapping mechanism, and preclinical work suggested it may restore leptin sensitivity.

How it works

In plain terms

Amylin is released with insulin when you eat and tells the brainstem that a meal has arrived. Cagrilintide is a long-lasting version of that signal, so meals feel satisfying sooner and for longer.

Technical detail

Cagrilintide activates amylin receptors — heterodimers of the calcitonin receptor with receptor activity-modifying proteins — in the area postrema and nucleus tractus solitarius. Effects include slowed gastric emptying, suppression of postprandial glucagon and reduced food intake. Preclinical data suggests amylin agonism may improve central leptin sensitivity, a mechanism not shared by incretins.

Pathways involved

Amylin receptor (CTR + RAMP) signalling in the area postrema
Hindbrain satiety circuits distinct from GLP-1 pathways
Gastric emptying and postprandial glucagon suppression
Proposed restoration of leptin sensitivity

Current research

Laboratory research

Analogue design work focused on preventing the amyloid aggregation that limited native amylin; receptor pharmacology confirms non-selective amylin/calcitonin agonism.

Animal research

Rodent obesity models show additive weight effects when amylin agonism is combined with GLP-1 agonism, and a distinct effect on food intake patterns.

Human research

Phase 2 monotherapy reported mean weight reductions in the region of 10–11% at 26 weeks. The CagriSema combination reported approximately 22.7% mean weight reduction at 68 weeks in REDEFINE-1 — a strong result that nonetheless fell below pre-trial expectations and moved the share price, a reminder that trial outcomes are judged against expectation as well as placebo. Diabetes-population results were more modest.

Ongoing research

The REDEFINE programme continues; regulatory submission timelines for CagriSema have been publicly discussed but no approval exists.

What is being investigated

Weight reduction as monotherapy
Combination with semaglutide (CagriSema)
Glycaemic control in type 2 diabetes
Satiety and food-intake regulation
Potential leptin sensitivity effects

These are research directions reported in the literature, not established effects or recommendations.

Risks, limitations and unknowns

Read this section before the rest

Not approved in any jurisdiction
Nausea and gastrointestinal effects remain common, particularly in combination
Amylin analogues historically carried hypoglycaemia risk when combined with insulin; relevance depends on the population
Long-term safety data does not exist
Reported trial results have varied against expectation, so published headline figures should be read alongside full trial reports

Evidence ratings

Laboratory studies

Strong

Analogue and receptor pharmacology well defined.

Animal studies

Moderate

Additive effects with incretins reproducible in rodents.

Human studies

Moderate

Phase 2 and Phase 3 data published; not yet approved.

Long-term safety

Limited

Trial-duration data only.

Comparisons

Cagrilintide vs Semaglutide

References

[1]Cagrilintide — indexed literature — PubMed, 2020–present
[2]CagriSema trial programme — ClinicalTrials.gov, current
[3]Amylin physiology and pharmacology — PubMed, 2000–present
Reference links open searches and records on PubMed and ClinicalTrials.gov so that every statement above can be traced to primary literature.

Frequently asked questions

What is cagrilintide?+

A long-acting synthetic analogue of the pancreatic hormone amylin, investigated for weight management alone and with semaglutide.

What is amylin?+

A hormone co-secreted with insulin by pancreatic beta cells that signals satiety, slows gastric emptying and suppresses postprandial glucagon.

Is cagrilintide approved?+

No. It remains investigational, including in the CagriSema combination.

What is CagriSema?+

A fixed-dose combination of cagrilintide and semaglutide designed to engage amylin and GLP-1 pathways simultaneously.

How much weight loss did CagriSema show?+

REDEFINE-1 reported approximately 22.7% mean reduction at 68 weeks, below the figure many analysts had anticipated.

Why combine amylin with GLP-1?+

The two act on partly separate satiety circuits, so their effects appear additive rather than redundant.

How does cagrilintide differ from pramlintide?+

Pramlintide is an approved amylin analogue requiring mealtime injections; cagrilintide is engineered for once-weekly dosing.

Does cagrilintide preserve muscle?+

Some preclinical work suggests a more favourable fat-to-lean loss ratio, but this has not been established in adequately powered human body-composition studies.

Continue your research

Semaglutide research

Combination protocols in trials

Weight-loss hub